 | |
| Clinical data | |
|---|---|
| Trade names | Revistel, Rivistel, or Rivestel |
| Other names | Iristel; RIV-2093; RIV2093; RIV 2093; Riv 2093; Riv-2093; Riv2093 |
| Drug class | DopamineD2 receptorantagonist;Antihypertensive agent;Antimigraine agent |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.072.585 |
| Chemical and physical data | |
| Formula | C17H26N4O4S |
| Molar mass | 382.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Alpiropride (INNTooltip International Nonproprietary Name; brand nameRevistel,Rivistel, orRivestel) is adopamineD2 receptorantagonist of thebenzamide group related tosulpiride.[1][2][3][4][5] It is described as anantihypertensive agent and has been marketed for use as anantimigrainemedication inPortugal.[1][4][2] The drug was first described by 1980[1] and was introduced for medical use by 1989.[4] It remained marketed in Portugal as late as 2000.[2]
